ERCC1 and colonic neoplasm: Similarly, ERCC1-19q13 gain was significantly associated with longer survival (HR: 0.45, 95% CI: 0.20-1.00, p = 0.049) in colon tumors, whereas only a non-significant trend was observed with TTR as endpoint in the colon subgroup (HR: 0.42, 95% CI: 0.16-1.07, p = 0.07).